Multiplexed Molecular Diagnostic Platforms
Develop rapid, integrated diagnostic tests for many diseases at once that are low cost.
From Jacob Trefethen’s essay:
“I would count success in the diagnostic row as: a multiplex diagnostic for at least 3 pathogens (i.e. flu + COVID does not count), available over the counter for use at home. Either a respiratory panel (e.g. flu + COVID + strep throat) or a fever panel (e.g. malaria + dengue + typhoid) would count. An at-home multiplex STI panel would be great (e.g. chlamydia + gonorrhea + syphilis)”.
Resources (2)
R&D Gaps (1)
Current diagnostic tests are costly or often offer only limited information, failing to reveal the cause of disease and delaying or preventing administration of available treatments. Moreover, early detection systems for emerging pathogens are fragmented, delaying critical public health intervention...